Journal
BLOOD
Volume 117, Issue 6, Pages 1917-1927Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-09-307140
Keywords
-
Categories
Funding
- Inserm
- Spanish Ministry of Science
- French Minister of Education
- CNRS
- Institut Curie
- Agence Nationale pour la Recherche
- Association pour la recherche sur le Cancer
- Belgian InterUniversity Attraction Pole
- Canceropole Ile-de-France
- Institut National du Cancer
- Universite Paris Descartes
Ask authors/readers for more resources
Chronic lymphocytic leukemia (CLL) is characterized by a clonal accumulation of mature neoplastic B cells that are resistant to apoptosis. Aiolos, a member of the Ikaros family of zinc-finger transcription factors, plays an important role in the control of mature B lymphocyte differentiation and maturation. In this study, we showed that Aiolos expression is up-regulated in B-CLL cells. This overexpression does not implicate isoform imbalance or disturb Aiolos subcellular localization. The chromatin status at the Aiolos promoter in CLL is defined by the demethylation of DNA and an enrichment of euchromatin associated histone markers, such as the dimethylation of the lysine 4 on histone H3. These epigenetic modifications should allow its upstream effectors, such as nuclear factor-kappa B, constitutively activated in CLL, to gain access to promoter, resulting up-regulation of Aiolos. To determine the consequences of Aiolos deregulation in CLL, we analyzed the effects of Aiolos overexpression or down-regulation on apoptosis. Aiolos is involved in cell survival by regulating the expression of some Bcl-2 family members. Our results strongly suggest that Aiolos deregulation by epigenetic modifications may be a hallmark of CLL. (Blood. 2011; 117(6): 1917-1927)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available